VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) is scheduled to present at the 17th Annual World Vaccine Congress Europe on Monday, October 10, 2016 at 3:45 PM CEST (9:45 AM ET). The event is being held at the Fairmont Rey Juan Carlos I in Barcelona, Spain.

During the presentation, eVLP Delivery of Novel Foreign Antigens Elicits Polyvalent Anti-tumor Immunity, Adam Buckley, VBI’s Vice President of Business Development, will provide an overview of VBI’s eVLP Platform and will summarize recent progress in VBI’s development of a therapeutic vaccine candidate to treat glioblastoma multiform (“GBM”) and medulloblastoma.Now in its 17th year, the World Vaccine Congress Europe is attended by decision makers from across Europe including leading research institutions, government regulators, and life sciences companies. For additional information, or to schedule a one-on-one meeting with VBI management, please contact ir@vbivaccines.com.

Event Details

  • Event: 17th Annual World Vaccine Congress Europe
  • Date: Monday, October 10, 2016
  • Time: 3:45 PM CEST (9:45 AM ET)
  • Location: Fairmont Rey Juan Carlos I in Barcelona, Spain
  • Event Website: http://bit.ly/wvc-europe-2016